ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Resolved
34days ago
Phase 3 readout · Jun 3, 2026
What's at stake
Phase 3 trial results for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma are due Jun 3, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).”